Gadoquatrane的临床前特性:一种新型四聚体大环高弛豫率钆基对比剂
该临床前研究表征了新型四聚体大环细胞外钆对比剂gadoquatrane的理化性质、药代动力学和磁共振成像特性。在1.41 T人血浆中,gadoquatrane每钆的r1弛豫率为11.8 mM⁻¹·s⁻¹(每分子47.2 mM⁻¹·s⁻¹),较现有大环钆对比剂高2倍以上(每分子高8倍);在人血清中21天未见钆释放,锌转金属化实验无Gd³⁺释放。大鼠胶质母细胞瘤模型中,相同钆剂量(0.1 mmol Gd/kg体重)下gadoquatrane的肿瘤-脑对比增强显著优于钆布醇;与钆特酸葡胺相比,钆剂量减少75%即可达到相似对比增强。
要点
- gadoquatrane为四聚体大环钆对比剂,每钆含1个内层水分子(q=1)。
- 人血浆中每钆r1弛豫率11.8 mM⁻¹·s⁻¹,较现有大环钆对比剂高2倍以上。
- 大鼠胶质母细胞瘤模型中,相同钆剂量下对比增强显著优于钆布醇。
核心结论
- 四聚体gadoquatrane是一种新型高效大环钆对比剂,具有高弛豫率和高稳定性、蛋白结合可忽略,药代动力学与现有大环钆对比剂基本一致,是进一步临床开发的优良候选药物。
研究设计与样本
- 临床前理化、药代动力学与MRI特性研究;r1弛豫率在1.41 T和3.0 T人血浆中测定,并行水与血浆核磁弛豫色散分析;人血清稳定性分析在pH 7.4、37°C下进行21天,与线性对比剂钆双胺及大环对比剂钆布醇比较;行锌转金属化实验评估动力学惰性;蛋白结合与血-血浆比在体外用大鼠和人血浆测定;药代动力学在大鼠中评估至注射后7天;MRI特性用GS9L大鼠胶质母细胞瘤模型研究。
关键影像表现/征象
- gadoquatrane在缓冲液中溶解度高(1.43 mol Gd/L,10 mM Tris-HCl,pH 7.4),亲水性高(1-丁醇/水中logP为-4.32),蛋白结合可忽略。
- 人血浆中gadoquatrane每钆r1弛豫率为11.8 mM⁻¹·s⁻¹(1.41 T、37°C、pH 7.4,对应每分子47.2 mM⁻¹·s⁻¹),较现有大环钆对比剂高2倍以上(每分子高8倍)。
- 核磁弛豫色散分析证实,在0.47至3.0 T临床相关磁场强度下,gadoquatrane人血浆r1弛豫率较现有大环钆对比剂高2倍以上。
- 大鼠胶质母细胞瘤模型中,相同钆剂量(0.1 mmol Gd/kg体重)下,gadoquatrane的肿瘤-脑对比增强定量评估显著优于钆布醇。
- 与钆特酸葡胺相比,gadoquatrane在钆剂量减少75%时达到相似对比增强,按分子剂量计减少90%。
诊断标准与关键数值
- 人血浆中gadoquatrane每钆r1弛豫率为11.8 mM⁻¹·s⁻¹(1.41 T、37°C、pH 7.4),对应每分子47.2 mM⁻¹·s⁻¹,较现有大环钆对比剂高2倍以上(每分子高8倍)。
- gadoquatrane在人血清中37°C下21天后钆释放量低于定量下限,锌转金属化实验中无Gd³⁺释放。
- 大鼠胶质母细胞瘤模型中,相同钆剂量0.1 mmol Gd/kg体重下gadoquatrane对比增强显著优于钆布醇;与钆特酸葡胺相比,钆剂量减少75%达到相似对比增强,分子剂量减少90%。
临床应用与阅片要点
- gadoquatrane所有配制制剂因四聚体结构及单位体积分子数较少而与血液等渗。
- gadoquatrane药代动力学特征(血浆消除、生物分布、回收率)与钆布醇相当,表现为快速细胞外分布和经肾以原形快速消除。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this report was to characterize the key physicochemical, pharmacokinetic (PK), and magnetic resonance imaging (MRI) properties of gadoquatrane (BAY 1747846), a newly designed tetrameric, macrocyclic, extracellular gadolinium-based contrast agent (GBCA) with high relaxivity and stability.
MATERIALS AND METHODS: The r1-relaxivities of the tetrameric gadoquatrane at 1.41 and 3.0 T were determined in human plasma and the nuclear magnetic relaxation dispersion profiles in water and plasma. The complex stability was analyzed in human serum over 21 days at pH 7.4 at 37°C and was compared with the linear GBCA gadodiamide and the macrocyclic GBCA (mGBCA) gadobutrol. In addition, zinc transmetallation assay was performed to investigate the kinetic inertness. Protein binding and the blood-to-plasma ratio were determined in vitro using rat and human plasma. The PK profile was evaluated in rats (up to 7 days postinjection). Magnetic resonance imaging properties were investigated using a glioblastoma (GS9L) rat model.
RESULTS: The new chemical entity gadoquatrane is a macrocyclic tetrameric Gd complex with one inner sphere water molecule per Gd ( q = 1). Gadoquatrane showed high solubility in buffer (1.43 mol Gd/L, 10 mM Tris-HCl, pH 7.4), high hydrophilicity (logP -4.32 in 1-butanol/water), and negligible protein binding. The r1-relaxivity of gadoquatrane in human plasma per Gd of 11.8 mM -1 ·s -1 (corresponding to 47.2 mM -1 ·s -1 per molecule at 1.41 T at 37°C, pH 7.4) was more than 2-fold (8-fold per molecule) higher compared with established mGBCAs. Nuclear magnetic relaxation dispersion profiles confirmed the more than 2-fold higher r1-relaxivity in human plasma for the clinically relevant magnetic field strengths from 0.47 to 3.0 T. The complex stability of gadoquatrane at physiological conditions was very high. The observed Gd release after 21 days at 37°C in human serum was below the lower limit of quantification. Gadoquatrane showed no Gd 3+ release in the presence of zinc in the transmetallation assay. The PK profile (plasma elimination, biodistribution, recovery) was comparable to that of gadobutrol. In MRI, the quantitative evaluation of the tumor-to-brain contrast in the rat glioblastoma model showed significantly improved contrast enhancement using gadoquatrane compared with gadobutrol at the same Gd dose administered (0.1 mmol Gd/kg body weight). In comparison to gadoterate meglumine, similar contrast enhancement was reached with gadoquatrane with 75% less Gd dose. In terms of the molecule dose, this was reduced by 90% when compared with gadoterate meglumine. Because of its tetrameric structure and hence lower number of molecules per volume, all prepared formulations of gadoquatrane were iso-osmolar to blood.
CONCLUSIONS: The tetrameric gadoquatrane is a novel, highly effective mGBCA for use in MRI. Gadoquatrane provides favorable physicochemical properties (high relaxivity and stability, negligible protein binding) while showing essentially the same PK profile (fast extracellular distribution, fast elimination via the kidneys in an unchanged form) to established mGBCAs on the market. Overall, gadoquatrane is an excellent candidate for further clinical development.
引用
- Lohrke, Berger, Frenzel, et al. Preclinical Profile of Gadoquatrane: A Novel Tetrameric, Macrocyclic High Relaxivity Gadolinium-Based Contrast Agent. Invest Radiol. 2022. PMID: 35703267. doi:10.1097/RLI.0000000000000889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。